| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | $152.52 | $10.13B | N/A |
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
http://www.zacks.com/stock/news/655819/4-solid-gene-therapy-buyout-bets-post-audentes-astellas-deal?cid=CS-ZC-FT-analyst_blog|industry_focus-655819
Dec 05, 2019 - Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
0
These 3 Value Stocks Are Absurdly Cheap Right Now
https://www.fool.com/investing/2019/11/22/these-3-value-stocks-are-absurdly-cheap-right-now.aspx?source=iedfolrf0000001
Nov 22, 2019 - These dirt cheap healthcare stocks could be poised for a major upswing in 2020.
0
Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal
http://www.zacks.com/stock/news/621292/sarepta-srpt-stock-down-despite-new-%2448m-gene-therapy-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-621292
Nov 15, 2019 - Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.
0
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
http://www.zacks.com/stock/news/610537/sarepta-srpt-q3-loss-widens-y-y-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-610537
Nov 08, 2019 - Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
0
Sarepta Therapeutics (SRPT) Q3 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/11/08/sarepta-therapeutics-srpt-q3-2019-earnings-call-tr.aspx?source=iedfolrf0000001
Nov 08, 2019 - SRPT earnings call for the period ending September 30, 2019.
0
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4304181-sarepta-therapeutics-inc-srpt-ceo-douglas-ingram-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare
Nov 08, 2019 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2019 Earnings Conference Call November 7, 2019 16:30 ET Company Participants Ian Estepan - Senior Vice President, Chief of Staff and Corporate Affairs Dougl
0
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates
http://www.zacks.com/stock/news/609069/sarepta-therapeutics-srpt-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-609069
Nov 07, 2019 - Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -26.87% and 1.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
0
What's in the Cards for Sarepta (SRPT) This Earnings Season?
http://www.zacks.com/stock/news/577120/whats-in-the-cards-for-sarepta-srpt-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-577120
Oct 22, 2019 - Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
0
Company News For Oct 7, 2019
http://www.zacks.com/stock/news/553042/company-news-for-oct-7-2019?cid=CS-ZC--corporate_summary-553042
Oct 07, 2019 - Companies in the news are: COST, BP, HPQ and SRPT
0
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript)
https://seekingalpha.com/article/4295175-sarepta-therapeutics-inc-srpt-ceo-douglas-ingram-presents-limb-girdle-muscular-dystrophy-type?source=feed_sector_transcripts
Oct 04, 2019 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Limb-Girdle Muscular Dystrophy Type 2E Functional Results Call October 4, 2019 08:00 AM ET Company Participants Ian Estepan - Senior Vice President, Chief of S
0
Page 1>